Halting the natural history of hepatitis B viral infection: A paradigm shift

Seminars in Liver Disease

Volumn 27, Issue SUPPL. 1, 2007, Pages 3-8

  Perrillo, Robert P ^a   Jacobson, Ira M ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Alanine aminotransferase; Cirrhosis; HBV DNA; Hepatitis B; Hepatocellular carcinoma; Treatment guidelines

Indexed keywords

ALANINE AMINOTRANSFERASE; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CONFERENCE PAPER; DISEASE COURSE; ENZYME ACTIVITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; VIRUS PATHOGENESIS;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PRACTICE GUIDELINES;

EID: 34548141753     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-984694     Document Type: Conference Paper

References (34)

1. World Heath Organization. Hepatitis B 2000. Available at: http://www.who.int/mediacentre/factsheets/fs204/en. Accessed June 6, 2006
2. Centers for Disease Control and Prevention (CDC). Incidence of acute hepatitis B: United States, 1990-2002. MMWR Morb Mortal Wkly Rep 2004;52:1252-1254
3. Beasley RP. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-1956
4. The Organ Procurement and Transplantation Network. Organ by diagnosis. Current U.S. waiting list. Available at: http://www.optn.org/latestData/step2. asp?. Accessed December 5, 2006
5. Lok AS, McMahon BJ; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B. Hepatology 2001;34:1225-1241
6. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539
7. Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660-1667
8. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004;39:804-810
9. Perrillo RP. Therapy of hepatitis B: viral suppression or eradication? Hepatology 2006;43(suppl 1):S182-S193
10. Liaw YF. The current management of HBV drug resistance. J Clin Virol 2005;34(suppl 1):S143-S146
11. Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005;25(suppl 1):9-19
12. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73
13. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686
14. Kim HC, Nam CM, Jee SH, et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004;328:983
15. Yang LM, Xu KC, Zhao YL, et al. Clinical significance of liver biopsy in chronic hepatitis B patients with persistently normal transaminase. Chin J Dig Dis 2002;3:150-153
16. Yuen MF, Yuan HJ, Wong DK, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005;54:1610-1614
17. Fattovich G, Rugge M, Brollo L, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986;6:167-172
18. Hoofnagle JH, Dusheiko GM, Seeff LB, et al. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981;94:744-748
19. Manesis EK, Papatheodoridis GV, Sevastianos V, et al. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol 2003;98:2261-2267
20. Evans AA, Fabre RE, Chen G, et al. Hepatitis B viral load is associated with the development of hepatocellular carcinoma (HCC). Hepatology 2004;40(suppl 1):602A
21. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-174
22. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002;36:1408-1415
23. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-68
24. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263
25. Zoulim F, Poynard T, Degos F, et al. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat 2006;13:278-288
26. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-791
27. Lai CL, Gane E, Hsu CW, et al. Two-year results from the GLOBE Trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudune (LDT) vs lamivudine. Hepatology 2006;44(suppl 1):222A
28. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722
29. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687-696
30. Heo J, Cho M, Cho BM, et al. Predictors of lamivudine resistance in patients with chronic hepatitis B infection. Korean J Hepatol 2007;13:157-165
31. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-1751
32. DiBisceglie A, Lai CL, Gane E, et al. Telbivudine GLOBE Trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology 2006;44(suppl 1):230A-231A
33. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006;44:1656-1665
34. Colonno RJ, Rose RE, Pokornowski K, et al. Four year assessment of entecavir resistance in nucleoside naive and lamivudine refractory patients. Presented at: 42nd Annual Meeting of the European Association for the study of Liver Disease; April 11-15, 2007; Barcelona, Spain